Cancer Research. 1997. 57. xxiv Sekulic, A., Midgen M.R., et. Al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. The New England Journal of Medicine. 2012. 366:23.

“Basal cell carcinoma, in general, is the most common form of skin cancer in the world,” says Dr. Bernstein. “One in eight Canadians will develop it during their lifetime.

Basal cell carcinoma, the most common form of skin cancer, can be highly disfiguring at advanced stages [2] Odomzo adds to company`s expanding portfolio of targeted treatments for skin cancer ...

“Advanced basal cell carcinoma is a persistent, painful and highly disfiguring cancer. While the primary systemic treatment options are hedgehog inhibitors, many patients will eventually ...

[3] Treatments on the horizon for locally advanced basal cell carcinoma. Cancer Letters (2024). [4] The incidence and clinical analysis of non-melanoma skin cancer. Scientific Reports (2021).

This dual-imaging approach could lead to more precise, less invasive skin cancer diagnostics in the future. By combining structural and chemical information, clinicians may be able to make faster and ...

Vismodegib is effective for treating advanced basal cell carcinoma (BCC) and basal cell nevus syndrome, but drug discontinuation is high because of adverse effects.

MISSISSAUGA, ON , Oct. 29, 2021 /CNW/ - Libtayo ® (cemiplimab) is now approved in Canada for the treatment of adults with locally advanced basal cell carcinoma (BCC) previously treated with a ...

In a study published in the Journal of Biomedical Optics, researchers at the Saint-Étienne University Hospital and ...

Basal Cell Carcinoma symptoms often include small, shiny bumps or lesions that can appear anywhere on the body. Though BCC grows slowly and rarely spreads to distant organs, it can invade nearby ...